Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Boston Scientific (BSX) stock shows strong growth, profitability, and a bullish technical setup, making it a top pick for a combined analysis strategy.
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
Boston Scientific (BSX) is a top technical breakout candidate with strong uptrend momentum and a high-quality consolidation pattern, signaling a potential near-term advance.
Growth is oxygen.
But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Boston Scientific has been treading water for the past six months, recording a small loss of 1.2% while holding steady at $104.10. The stock also fell short of the S&P 500’s 5.5% gain during that period.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
The FDA is reviewing Boston Scientific's defibrillator leads after reports of rising shock impedance and 16 related deaths. Healthcare providers are advised to monitor patients closely.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Boston Scientific (NYSE:BSX) and the rest of the medical devices & supplies - diversified stocks fared in Q2.
Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 22.8% year on year to $5.06 billion. Guidance for next quarter’s revenue was optimistic at $4.97 billion at the midpoint, 2.2% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 4.1% above analysts’ consensus estimates.
